Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 31, 2023 08:00 ET | Source: Rain Oncology Inc.

Rain Oncology to Participate in the 2023 Guggenheim Healthcare Talks Oncology Day Conference

NEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate,...
January 23, 2023 08:00 ET | Source: Rain Oncology Inc.

Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology

– Intermittent dosing of milademetan, an inhibitor of the p53-MDM2 complex, potentially exhibits an avenue to address historical issues with cytopenias with this class of compounds– – Phase 1 data in...
December 29, 2022 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics Inc. Announces Name Change to Rain Oncology Inc.

NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead...
December 27, 2022 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics to Participate in the 41st Annual J.P. Morgan Health Care Conference

NEWARK, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product...
August 04, 2022 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma

– Phase 3 MANTRA trial completed enrollment five months ahead of previous guidance – – MANTRA topline data anticipated in 1H 2023 – – Management to host 2Q 2022 Earnings Call today at 5:00 PM...
July 21, 2022 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics to Report Second Quarter 2022 Financial Results and Highlights of Recent Progress on August 4, 2022

NEWARK, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report...
May 18, 2022 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics to Present on Milademetan at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

NEWARK, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), ("Rain"), a late-stage biotechnology company developing precision oncology therapeutics, today announced it...
April 20, 2022 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics to Report First Quarter 2022 Financial Results and Highlights of Recent Progress on May 4, 2022

NEWARK, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report...
April 01, 2022 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics Announces a Poster Presentation and Trials In Progress at the American Association for Cancer Research (AACR) Annual Meeting 2022

NEWARK, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced a poster...
February 24, 2022 08:00 ET | Source: Rain Therapeutics

Rain Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Highlights of Recent Progress on March 3, 2022

NEWARK, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report...